Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,799 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07244510RecruitingPhase 2
New Treatment for Moderate to Severe Hidradenitis Suppurativa
This trial tests a new medicine called SCT650C for people with moderate to severe hidradenitis suppurativa (HS). The goal is to see if it can reduce painful bumps and abscesses better than current treatments.
Samsun, TurkeyAges 18 years+ - NCT07246096RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
ShanghaiAges 18–70 - NCT07246564RecruitingPhase 4
Rozanolixizumab for Generalized Myasthenia Gravis in Chinese Adults
This study tests an investigational drug called rozanolixizumab for Chinese adults with generalized myasthenia gravis who have a specific antibody (AChR or MuSK) and symptoms that still affect daily activities. It aims to see if the drug helps improve muscle strength and quality of life.
BeijingAges 18 years+ - NCT07246668RecruitingPhase 2
Carbon ion radiation with immunotherapy for advanced liver cancer
This trial tests a combination of carbon ion radiation therapy with two drugs, atezolizumab and bevacizumab, for people with advanced liver cancer that cannot be surgically removed. The goal is to see if this approach is safe and effective.
SeoulAges 20 years+ - NCT07247266RecruitingPhase 1
Testing JTE-162 for CAPS (FCAS and MWS)
This study tests an experimental drug called JTE-162 for people with certain types of CAPS (cryopyrin-associated periodic syndrome). The goal is to see if it's safe and can help control symptoms like fever, rash, and joint pain.
North York, OntarioAges 18–80 - NCT07250542RecruitingPhase 2
Fasudil with immunotherapy for advanced prostate cancer
This trial tests a combination of fasudil hydrochloride and immunotherapy for men with metastatic castration-resistant prostate cancer that has stopped responding to chemotherapy and hormone therapy. The goal is to see if this new approach can help control the cancer.
NanjingAges 18–85 - NCT07251023RecruitingPhase 3
Testing a new drug for Alzheimer's dementia
This study tests whether a new drug called Latrepirdine (DMB-I) is safe and effective for people with mild to moderate Alzheimer's dementia. It may help slow cognitive decline when added to current treatment or used alone.
Kazan'Ages 60–90 - NCT07617597RecruitingPhase 3
Testing deuruxolitinib for severe hair loss in Japanese adults
This study tests whether a new drug called deuruxolitinib can help regrow hair in people with alopecia areata (an autoimmune condition causing patchy hair loss). The drug works by blocking certain immune signals that attack hair follicles.
AsahikawaAges 18–65 - NCT06241118RecruitingPhase 3
New injection for eczema not helped by other advanced treatments
This study tests a new injection called amlitelimab for teens and adults with moderate-to-severe eczema that hasn't gotten better with other advanced treatments like biologics or JAK inhibitor pills. It's given along with steroid creams to see if it can improve symptoms.
Birmingham, AlabamaAges 12 years+ - NCT07500090RecruitingPhase 3
Study of HBS-301 for idiopathic hypersomnia
This trial tests a new medication, HBS-301, in people with idiopathic hypersomnia (a condition causing excessive sleepiness without clear cause). It aims to see if the drug improves wakefulness and is safe.
Birmingham, AlabamaAges 18 years+ - NCT05066217RecruitingPhase 3
Study tests clemizole for Lennox-Gastaut seizures
This Phase 3 trial studies whether clemizole helps reduce seizures in people with Lennox-Gastaut syndrome (LGS) and checks safety. If you have LGS and meet the seizure and heart-safety requirements, this could be an option to explore.
Little Rock, ArkansasAges 2–55 - NCT07516288RecruitingPhase 1
Second CAR-DC Cell Infusion for Advanced Heart Failure
This trial tests a second dose of specialized immune cells (called CAR-DC) in patients with severe dilated cardiomyopathy (a weakened heart muscle) who received one dose before but saw their heart function decline back to baseline. The goal is to see if a second dose is safe and can improve heart function when the first treatment's benefits wore off.
Hangzhou, Zhejiang / 浙江Ages 18–75 - NCT05492578Enrolling by invitationPhase 2/Phase 3
Long-term follow-up of amlitelimab for moderate to severe eczema
This trial studies the long-term safety and effectiveness of amlitelimab in people with moderate to severe atopic dermatitis (eczema). You may be eligible if you previously joined an amlitelimab eczema study and are continuing into a longer follow-up phase.
Birmingham, AlabamaAges 12 years+ - NCT07251309RecruitingPhase 3
Study of WS016 for treating high potassium levels
This trial tests a new drug called WS016 to lower high potassium levels in adults. High potassium can be dangerous for your heart, and this study aims to find out if WS016 is safe and effective.
Bengbu, AnhuiAges 18 years+ - NCT07252323Recruiting
Carbon ion radiotherapy for liver cancer after TARE
This trial tests a new type of radiation therapy (carbon ion radiotherapy) for people with liver cancer that has not been fully controlled after prior TARE treatment. It aims to see if it is safe and effective for treating the remaining or returning cancer.
SeoulAges 20 years+ - NCT07255534Recruiting
Digital therapy for shoulder recovery after rotator cuff repair
This trial tests a digital app-based therapy to improve shoulder function after rotator cuff repair surgery. It uses your smartphone to guide your rehabilitation exercises at home.
Seoul, Republic of KoreaAges 19 years+ - NCT07256522Recruiting
Comparing treatments for trigger finger
This study compares three non-surgical treatments for a single trigger finger: a splint, paraffin wax, and a type of mud therapy. It aims to find which works best for improving finger movement and reducing pain.
Konya, KonyaAges 18–75 - NCT07257653RecruitingPhase 2
Cetuximab beta plus fruquintinib with or without immunotherapy for first-line advanced colorectal cancer
This trial tests a combination of two targeted drugs (cetuximab beta and fruquintinib) with or without an immunotherapy drug for people with a specific type of advanced colorectal cancer that has not been treated before. It aims to see if this approach is safe and effective for those whose tumors have certain genetic markers (RAS and BRAF wild type).
Hangzhou, ZhejiangAges 10–85 - NCT07257887Recruiting
Testing OROXID oral solution for gum disease
This trial tests a mouth rinse (OROXID) to see if it helps treat advanced gum disease (periodontitis). You may qualify if you have at least three deep gum pockets and have not had dental cleanings or used antibiotics recently.
LjubljanaAges 18 years+ - NCT07260669RecruitingPhase 2
Vipoglanstat for endometriosis-related pelvic pain
This study tests an investigational drug called Vipoglanstat for women with endometriosis-related pelvic pain that happens even when they are not on their period. The goal is to see if it can reduce pain and improve quality of life.
BlagoevgradAges 18–44 - NCT07261644RecruitingPhase 3
Study of a new drug for active ankylosing spondylitis
This study tests a new medication (called 608) for adults with active ankylosing spondylitis (AS). It aims to see if the drug can reduce AS symptoms and improve quality of life.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07265284RecruitingPhase 3
IBI112 for teens with moderate to severe plaque psoriasis
This study tests a new medicine called IBI112 for teens aged 12–18 with moderate to severe plaque psoriasis. It aims to see if the medicine is safe and can help clear skin better than placebo.
Beijing, Beijing MunicipalityAges 12–18 - NCT07266181RecruitingPhase 1
CAR-T cell therapy for tough-to-treat membranous nephropathy
This trial tests whether specially engineered immune cells (CAR-T cells) can help people with a kidney condition called primary membranous nephropathy that has not improved with standard treatments. The goal is to see if this therapy can reduce protein in the urine and protect kidney function.
Xi'an, ChinaAges 18 years+ - NCT07266493RecruitingPhase 2
Envafolimab plus chemo for esophageal cancer before surgery
This trial tests a new immunotherapy drug (Envafolimab) combined with standard chemotherapy before surgery for esophageal cancer that has not spread far. The goal is to see if this combination can shrink tumors and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,799 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.